System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Olivier Dereure is an expert in Dermatology at University Hospital of Montpellier (France). As of October 2026, ScienceLeadR ranks Olivier Dereure in the top 1% of experts worldwide for Sexually Transmitted Diseases and Skin Diseases, Vesiculobullous. Olivier Dereure has authored 755 publications, the most recent in 2026, and is an investigator in 17 clinical trials, 4 of them ongoing. SLR score: 2,059 (community average: 125). How the SLR is computed.

LeadR Profile

Olivier Dereure University Hospital of Montpellier France
2 059 ScienceLeadR Reputation 2059

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Hematology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026
Source: PubMed

Hôpital Saint Eloi

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 755

Citations

Citations: 10 415 1st author: 66 Last author: 124 Unique author: 150

Main journals

Ann Dermatol Venereol 324
Br J Dermatol 45
Acta Derm Venereol 37
Contact Dermatitis 36
Annales de dermatologie et de vénéréologie, FMC 27

Best Journals

J Clin Oncol 7
Ann Oncol 5
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Inflammatory rheumatic diseases under mogamulizumab: a multicenter series of 11 cases.
PMID 42858804 — lymphoma, adrenal cortex hormones, arthritis, rheumatic diseases, therapeutics, methotrexate		Joint Bone Spine20260
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.
PMID 42791653 — cells, merkel cells, somatostatin, neoplasms, therapeutics, dermatology, carcinoma, merkel cell		Cancer Med20260
A New Case of Severe Allergic Contact Dermatitis Following a Recreational Exposure to Epoxy Resin.
PMID 42547269 — dermatitis, dermatitis, allergic contact, epoxy resins, dermatitis, contact		Contact Dermatitis20260
Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome.
PMID 42490360 — syphilis, sezary syndrome, dermatology		Br J Dermatol20260
Severe Ulceronecrotic Evolution during Mogamulizumab Treatment in a Patient with Primary Cutaneous Peripheral T-cell Lymphoma.
PMID 42007812 — cells, sexually transmitted diseases, lymphoma, therapeutics, lymphoma, t-cell, peripheral, t-lymphocytes, dermatology, lymphoma, t-cell		Acta Derm Venereol20260

Clinical Studies 17

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

N/A 7
Phase 3 6
Phase 2 3
Phase 4 1

By status:

Completed 5
Recruiting 4
Unknown 4
Active not recruiting 3
Not yet recruiting 1

By type:

Interventional 11
Observational 6

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 1
multicentric5to9 1
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment
NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma		N/ARecruiting2021
Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I III Merkel Cell Carcinoma
NCT06448611 — radiotherapy, cells, merkel cells, blood, neoplastic cells, circulating, neoplasms, aftercare, research, therapeutics, hematologic tests, carcinoma, merkel cell, carcinoma		N/ANot yet recruiting2024
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
NCT05898308 — injections, skin, antibodies, adrenal cortex hormones, skin diseases, desmogleins, biomarkers, maintenance, rituximab, precision medicine, acantholysis, therapeutics, pemphigus		Phase 4Recruiting2024
Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors
NCT05649683 — cytokines, skin, melanoma, neoplasms, immunotherapy, aftercare, drug-related side effects and adverse reactions, therapeutics		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS